Article

Pembrolizumab ‘new standard of care’ in advanced PD-L1-rich NSCLC
Pembrolizumab was superior to chemotherapy in stage IV NSCLC with PD-L1 expression of 50% or more.
Pembrolizumab was superior to chemotherapy in stage IV NSCLC with PD-L1 expression of 50% or more.
Unmet dental needs and untreated dental decay represent a significant disease burden for children and adults.
BALTIMORE – Patients admitted with acute ischemic stroke (AIS) with preexisting major depressive disorder (MDD) are less likely to die while in...
COPENHAGEN – The checkpoint inhibitor atezolizumab improved overall survival of advanced non–small-cell lung cancer, compared with docetaxel.
Researchers have identified a genetic variant associated with inherited elevated basal serum tryptase levels and linked to a distinct group of...
The clinical quality of outpatient care for adults in the United States did not improve consistently from 2002 to 2013.
A 74-year-old man presented to our outpatient dermatology clinic with an asymptomatic umbilical lesion of unknown duration. The patient believed...
The troubling, frustrating part of acne: the persistent acne scars that are often a prolonged battle for most of our patients.
Can an objective measurement of critical illness inform intensive care unit (ICU) transfer timeliness?